Our cell engineering services cater to both tool or reagent and biological product development requirements. We have strong expertise to generate recombinant or stable cell lines for complex and wide protein class targets such as:
RTKs GPCRs Ion channels Immune modulation ligands or receptors Fc-gamma receptors GPI-anchored TNF-receptor superfamily Cell adhesion molecules Transporters Co-receptors Reporter genes
We are well-versed in working with different cellular backgrounds such as established cancer cell lines and primary cells. Hard-to-transfect cell lines required for binding studies, functional assays, immunization in vitro or in vivo screening and efficacy evaluation applications are successfully engineered to achieve the desired attributes.
For biologics programs, we have experience of product development for mAbs, immune-fusion molecules and cytokines. The typical activities includes: transfection, selection, Limiting dilution, media/feed screening, cell line characterization, research cell banking and protein production
pcDNA series, pLVX and pGIPZ / pTRIPZ lentiviral vector series, pCHO1.0, pOptivec, pGL and in-house modified vector systems
Strong framework data recording and traceability
Recombinant cell lines for wide protein classes
In-house lentiviral platform for difficult to express reagent proteins
Extensive experience working with various vector or cell line systems
JUNE 28, 2022
Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...Read More
JANUARY 04, 2021
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...Read More
We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.